A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.
Phase 3
Completed
- Conditions
- Hypertension, Diabetes Mellitus
- Registration Number
- NCT00219089
- Lead Sponsor
- Novartis
- Brief Summary
To demonstrate the efficacy and safety of aliskiren given to patients with both hypertension and diabetes mellitus
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 839
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in mean sitting diastolic blood pressure after 8 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline to week 8 endpoint in mean sitting systolic blood pressure Diastolic blood pressure less than 90 mmHg or reduction of 10 mmHg or greater from baseline after 8 weeks Change from baseline to week 4 endpoint in mean sitting diastolic blood pressure
Trial Locations
- Locations (1)
Novartis Pharmaceuticals
🇺🇸East Hanover, New Jersey, United States